PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction / 中华男科学杂志
National Journal of Andrology
;
(12): 355-359, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-689750
ABSTRACT
Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) is a common disease with frequent occurrence in elderly men, and its incidence shows a significant positive correlation with age. Evidence has confirmed that BPH/LUTS is closely related to erectile dysfunction (ED) and significantly affects the quality of life of elderly males. Phosphodiesterase 5 inhibitors (PDE5i) can improve both ED and BPH/LUTS of the patients and PDE5 is expected to be a new therapeutic target for BPH/LUTS with ED. This review explores the structure and function of PDE5 and the action mechanisms of PDE5i so as to provide a more effective strategy for the clinical treatment of BPH/LUTS with ED.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prostatic Hyperplasia
/
Quality of Life
/
Therapeutic Uses
/
Drug Therapy
/
Drug Therapy, Combination
/
Phosphodiesterase 5 Inhibitors
/
Lower Urinary Tract Symptoms
/
Erectile Dysfunction
Type of study:
Diagnostic study
Limits:
Aged
/
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS